Research Question : What are the long-term effects and safety profiles of current pharmacological and surgical treatments for the Parkinson’s disease, and how can their efficacy be optimized?
Thesis Statement;
Current pharmacological and surgical procedures for the Parkinson’s disease (also known as PD) have shown efficacy in managing symptoms and improving quality of life for patients, but optimizing their effectiveness requires more of a personalized approach, which is; regular monitoring, and a multidisciplinary care team.
Introduction:
The Parkinson’s disease (in short form PD), is a progressive neurological disorder that tends to affect movement, primarily due to the loss of dopamine-producing brain cells. The main symptoms of this disease includes :
Tremors
Stiffness
Restriction of movement
Loss of senses
Unstable walking posture
Mask-like facial expressions
While there is no cure for Parkinson’s disease, there have been various pharmacological and surgical treatments which have been designed to comparatively manage it’s symptoms and to improve the patient’s quality of life. In this essay, we will delve deeply into the long-term effects and safety profiles for the disease, whilst also exploring how their efficacy can be optimized.
Pharmacological Treatments:
One of the mainstays of pharmacological treatments for Parkinson’s is levodopa, which is a precursor of dopamine that helps in the replenish of the brain’s depleted dopamine levels. The treatment of levodopa is often combined with carbidopa, to enhance it’s effectiveness and to reduce the side effects such as nausea/vomiting. While levodopa is highly effective in alleviating the motor symptoms of PD, long-term uses can lead to motor fluctuations and dyskinesia, which are involuntary movements that can be deliberating.
Another class of medications commonly used in the treatments of the Parkinson’s disease is dopamine agonists, such as pramipexole and ropinirole. These drugs mimic the action of dopamine in the brain and help in alleviating the motor symptoms. However, dopamine agonists are associated with side effects which include;
Hallucinations
Impulse control disorders
Orthostatic hypertension
Additionally, long-term usage of dopamine agonists have a significant increased risk of developing; impulse control disorders, compulsive gambling, shopping, and eating.
In recent years, researchers have been exploring the potential benefits of adenosine A2A receptor antagonists in the treatment of Parkinson's disease. These drugs work by blocking the adenosine A2A receptor, which is thought to play a role in the regulation of dopamine signalling in the brain. Preliminary studies have shown promising results in reducing motor symptoms and improving motor function in PD patients. However, further research is needed to determine the long-term safety and efficacy of these drugs.
Surgical Treatments:
Deep brain stimulation (also known as DBS), is a surgical procedure that involves the implantation of electrodes in specific regions of the brain and use a pace-maker like machine to deliver electrical impulse. DBS has shown a great amount of effectiveness in terms of alleviating the motor symptoms and reducing medication dosage in patients with advanced Parkinson’s disease. However, DBS is not without risks, this includes infection, bleeding, and cognitive decline. Long-term outcomes of DBS patients with PD are generally positive, with improvements in motor functions and quality of life for up to 10 years of post-surgery condition.
Another surgical treatment option for Parkinson’s disease is ablative surgery, such as pallidotomy or thalamotomy, which involves in destroying a specific part of the brain/areas that are responsible for the motor symptoms of PD. While ablative surgery can provide significant symptom relief in some patients, it is considered a last-resort treatment due to its irreversible nature and potential side effects, such as cognitive deficits and speech problems.
Optimizing efficacy:
In order to optimize the efficacy of the surgical and pharmacological treatments for the Parkinson’s disease, a personalized treatment approach is extremely essential. Healthcare providers should tailor the treatments accordingly to each patient’s specific symptoms, disease progression, and individual preferences. Regular monitoring and adjustments to medication dosages help in minimizing the side effects and maximizing the benefits.
Furthermore, a multidisciplinary approach to the management of Parkinson's disease is crucial. In addition to pharmacological and surgical treatments, physical therapy, occupational therapy, speech therapy, and psychosocial support can all play a significant role in improving patients' quality of life and function.
Conclusion:
In conclusion, current pharmacological and surgical treatments for Parkinson's disease have shown efficacy in alleviating motor symptoms and improving quality of life for patients. However, long-term use of these treatments can be associated with various side effects and risks. By adopting a personalized approach to treatment, regularly monitoring patients' symptoms, and incorporating a multidisciplinary care team, healthcare providers can optimize the efficacy of current treatments and enhance outcomes for individuals living with Parkinson's disease. Further research is needed to explore novel treatment options and improve long-term outcomes for PD patients.
Written by: Pronita Kesavarapu
SOURCES:
1. Connolly, B. S., & Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA, 311(16), 1670-1683.
2. Grosset, K. A., Grosset, D. G., & Grosset, J. (2016). A review of the pharmacological management of Parkinson's disease. Journal of Parkinson's Disease, 6(1), 29-47.
3. Olanow, C. W., & Obeso, J. A. (2018). The significance of defining preclinical or prodromal Parkinson's disease. Movement Disorders, 33(11), 1729-1734.
4. Fasano, A., & Aquino, C. C. (2015). Challenges and future directions for DBS research in Parkinson's disease. Frontiers in integrative neuroscience, 9, 51.
5. Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., ... & Balzer‐Geldsetzer, M. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine, 355(9), 896-908.
6. Ahlskog, J. Eric (2011). "Parkinson's disease: symptoms, diagnosis and treatment." Retrieved from https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055
7. Kalia, Lorraine V., and Lang, Anthony E. (2015). "Parkinson's disease." The Lancet, 386(9996), 896-912.
8. Henshaw, Karen, and Edwards, Marie (2017). "Management of Parkinson's disease." Retrieved from https://www.nursingtimes.net/clinical-archive/neurology/management-of-parkinsons-disease-02-01-2017/
9. Staud, Sonja, et al. (2020). “New targets for drugs to treat Parkinson's disease: what is the role of the A2A adenosine receptor?”. Journal of Medicinal Chemistry, 63(11), 5691-5705.
10. Weaver, Frances M., et al. (2002). "Stereochemistry of L-DOPA-derived cardioprotective agents." Bioorganic and Medicinal Chemistry Letters, 12(5), 915-918.
Comments